Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

Quick Read AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus by $280M, while Skyrizi surged 30.9% YoY to $4.48B ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

AbbVie (ABBV) stock gains as the company raised its full-year earnings outlook despite a mixed performance in Q1 2026. Read ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services Evernorth Health, a wholly owned subsidiary of Cigna ...

AbbVie is scheduled to report Q1 earnings on April 29, before market open, with analysts expecting growth recovery both in ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...